Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

UBS Warburg Cuts Immunomedics to 'Hold'


UBS Warburg downgraded Immunomedics (IMMU) to hold from buy.

Analyst Andrew Gitkin says his downgrade is based on valuation. He believes the lack of near-term catalysts is likely to limit potential upside from current levels, and says Immunomedics is increasingly sensitive at current valuation levels to regulatory and competitive dynamics that may directly impact product development and commercialization strategy for its lead product, LymphoCide. Gitkin thinks it may take longer to get LymphoCide to market than originally expected. He sees a $0.04 fiscal 2002 (June) loss, and a $0.19 fiscal 2003 loss. He also cut the $28 target to $22


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus